Investors Buy Large Volume of OPKO Health Call Options (NASDAQ:OPK)

OPKO Health, Inc. (NASDAQ:OPK) was the recipient of unusually large options trading activity on Tuesday. Stock traders bought 5,038 call options on the company. This is an increase of approximately 101% compared to the typical volume of 2,501 call options.

Insiders Place Their Bets

In other news, CEO Phillip Md Et Al Frost purchased 125,000 shares of the business’s stock in a transaction that occurred on Thursday, April 10th. The shares were acquired at an average cost of $1.36 per share, for a total transaction of $170,000.00. Following the transaction, the chief executive officer now directly owns 214,001,448 shares of the company’s stock, valued at approximately $291,041,969.28. The trade was a 0.06 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. In the last 90 days, insiders acquired 1,464,971 shares of company stock valued at $2,268,692. Company insiders own 49.69% of the company’s stock.

Institutional Trading of OPKO Health

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Assenagon Asset Management S.A. increased its position in shares of OPKO Health by 9.1% during the 1st quarter. Assenagon Asset Management S.A. now owns 935,100 shares of the biotechnology company’s stock worth $1,563,000 after purchasing an additional 78,362 shares during the last quarter. SG Americas Securities LLC acquired a new position in OPKO Health during the first quarter worth $585,000. Pallas Capital Advisors LLC bought a new stake in OPKO Health during the first quarter worth $43,000. Wealth Enhancement Advisory Services LLC lifted its stake in OPKO Health by 75.3% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 12,417 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of OPKO Health by 24.5% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 753,380 shares of the biotechnology company’s stock valued at $1,107,000 after acquiring an additional 148,322 shares during the period. Institutional investors and hedge funds own 64.63% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a report on Monday, April 7th. StockNews.com upgraded OPKO Health from a “sell” rating to a “hold” rating in a report on Monday, March 3rd. Finally, Barrington Research restated an “outperform” rating and set a $2.25 target price on shares of OPKO Health in a report on Wednesday, March 12th.

OPKO Health Stock Up 1.4 %

NASDAQ:OPK traded up $0.02 during trading hours on Tuesday, reaching $1.44. 1,084,637 shares of the stock were exchanged, compared to its average volume of 3,933,154. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. OPKO Health has a twelve month low of $1.15 and a twelve month high of $2.04. The stock has a market cap of $967.03 million, a PE ratio of -7.58 and a beta of 1.78. The firm has a 50 day moving average of $1.68 and a 200 day moving average of $1.58.

OPKO Health (NASDAQ:OPK) last announced its earnings results on Thursday, February 27th. The biotechnology company reported $0.01 EPS for the quarter, topping the consensus estimate of ($0.08) by $0.09. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The business had revenue of $183.60 million during the quarter, compared to analysts’ expectations of $155.42 million. On average, equities analysts expect that OPKO Health will post -0.25 earnings per share for the current year.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.